Protocol Document: N0574
Protocol Number: N0574
Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases
Trial Type: Clinical

Protocol Document: N0779
Protocol Number: N0779
Phase II Study of Vorinostat (SAHA) in Combination with Bortezomib (PS-341) in Patients with Recurrent Glioblastoma Multiforme
Trial Type: Clinical

Protocol Document: N0272 (study1ArmC suspended)
Protocol Number: N0272 (study1ArmC suspended)
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) In Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Trial Type: Clinical

Protocol Document: R0614
Protocol Number: R0614
Randomized, Phase III Double Blind, Placebo Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole Brain Radiotherapy
Trial Type: Clinical

Protocol Document: B40
Protocol Number: B40
Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable reast Cancer Evaluating the Effect on Pathologic Complete Response of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens
Trial Type: Clinical

Protocol Document: IBCSG24-02
Protocol Number: IBCSG24-02
Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast
Trial Type: Clinical

Protocol Document: MA.17R
Protocol Number: MA.17R
Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed iwth Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in MA.17 Study)
Trial Type: Clinical

Protocol Document: S0221
Protocol Number: S0221
Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer.
Trial Type: Clinical

Protocol Document: S0307
Protocol Number: S0307
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
Trial Type: Clinical

Protocol Document: 893052
Protocol Number: 893052
Phase III Trial of Adjuvant Therapy with Tamoxifen Alone or combined with Fluoxymesterone in Post-Menopausal Women with Resected Estrogen Receptor Positive Breast Cancer.
Trial Type: Clinical

Protocol Document: E2197
Protocol Number: E2197
Phase III Study of Adriamycin/Taxotere vs. Adriamycin/Cytoxan in Adjuvant Treatment of Node+ and High Rise Node- Breast Cancer
Trial Type: Clinical

Protocol Document: N0336
Protocol Number: N0336
Phase II Trial of Raf Kinase Inhibitor BAY 43-9006 as Single Oral Agent in Patients with Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane
Trial Type: Clinical

Protocol Document: N063I
Protocol Number: N063I
Charnges in Breast Density and Plasma Hormone Levels After One Year of Aromatase Inhibitor Therapy
Trial Type: Clinical

Protocol Document: S0012
Protocol Number: S0012
A COMPARATIVE RANDOMIZED STUDY OF STANDARD DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY WEEKLY PACLITAXEL VS. WEEKLY DOXORUBICIN AND DAILY ORAL CYCLOPHOSPHAMIDE PLUS G-CSF FOLLOWED BY WEEKLY PACLITAXEL AS NEOADJUVANT THERAPY FOR INFLAMMATORY AND LOCALLY ADVANCED BREAST CANCER
Trial Type: Clinical

Protocol Document: B-39
Protocol Number: B-39
A RANDOMIZED PHASE III STUDY OF CONVENTIONAL WHOLE BREAST IRRADIATION (WBI) VERSUS PARTIAL BREAST IRRADIATION (PBI) FOR WOMEN WITH STAGE 0, I, OR II BREAST CANCER.
Trial Type: Clinical

Protocol Document: B 44I - call for consent
Protocol Number: B 44I - call for consent
Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2 Positive Node-Positive or High Risk Node Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab
Trial Type: Clinical

Protocol Document: N063D
Protocol Number: N063D
ALTTO Study. Ajuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study. A Randomized, Multi-Center, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, their sequence and their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
Trial Type: Clinical

Protocol Document: N0733
Protocol Number: N0733
Randomized Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 in Patients with HER2+ Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane
Trial Type: Clinical

Protocol Document: RC0639
Protocol Number: RC0639
Phase II Study of Cardiac Safety and Tolerability of an Adjuvant chemotehrapy plus Trastuzumab with Lapatinib in Patients with Resected HER2+ Breast Cancer
Trial Type: Clinical

Protocol Document: B-37
Protocol Number: B-37
A RANDOMIZED CLINICAL TRIAL OF ADJUVANT CHEMOTHERAPY FOR RADICALLY RESECTED LOCO-REGIONAL RELAPSE OF BREAST CANCER
Trial Type: Clinical

Protocol Document: E1105
Protocol Number: E1105
Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab for Patients with Her-2/NEU Over-Expressing Metastatic Breast Cancer
Trial Type: Clinical

Protocol Document: N0539 - SUSPENDED
Protocol Number: N0539 - SUSPENDED
Phase II Trial of Fulvestrant and Bevacizumab in Patients with Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor
Trial Type: Clinical

Protocol Document: S0226
Protocol Number: S0226
PHASE III RANDOMIZED TRIAL OF ANASTROZOLE VERSUS ANASTROZOLE AND FULVESTRANT AS FIRST LINE THERAPY FOR POST MENOPAUSAL WOMAN WITH METASTATIC BREAST CANCER
Trial Type: Clinical

Protocol Document: S0500
Protocol Number: S0500
Randomized Phase III Trial to Test the Strategy of Changing Therapy vs. Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment.
Trial Type: Clinical

Protocol Document: PACCT-1
Protocol Number: PACCT-1
Program for the Assessment of Clinical Cancer Tests
Trial Type: Clinical

Protocol Document: C70301 (substudy to C40101)
Protocol Number: C70301 (substudy to C40101)
Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Node-Negative Breast Cancer
Trial Type: Clinical

Protocol Document: CT-40101
Protocol Number: CT-40101
Cyclophosphamide and Doxorubicin (CA) (4 vs. 6 Cycles) Versus Paclitaxel (4 vs. 6 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A 2X2 Factorial Phase III Randomized Study
Trial Type: Clinical

Protocol Document: B 42
Protocol Number: B 42
Clniical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of Aromatase Inhibitor (AI) or Tamoxifen Followed by AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Postive Cancer
Trial Type: Clinical

Protocol Document: RC0731
Protocol Number: RC0731
Phase II Randomized Study of Sorafenib Compared to Placebo When Administered in Combination with Aromatase Inhibitors for Post-Menopausal Women with Metastatic Breast Cancer
Trial Type: Clinical

Protocol Document: Z1031
Protocol Number: Z1031
Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane, Letrozole or Anastrozole in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
Trial Type: Clinical

Protocol Document: E2Z04
Protocol Number: E2Z04
Quality of Life in Younger Breast Cancer Survivors
Trial Type: Clinical

Protocol Document: C90202
Protocol Number: C90202
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Early vs. Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone.
Trial Type: Clinical

Protocol Document: E5597
Protocol Number: E5597
Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer
Trial Type: Clinical

Protocol Document: MC04CC
Protocol Number: MC04CC
Phase III Randomized Study of the Effects of Parental Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin alfa for Cancer Patients with Chemotherapy-Associated Anemia
Trial Type: Clinical

Protocol Document: N04C2
Protocol Number: N04C2
An Exploratory, Randomzied, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR Depot) for Symptomatic Ascites in Cancer Patients
Trial Type: Clinical

Protocol Document: N05C5
Protocol Number: N05C5
Phase III Randomized, Placebo-Controlled, Double-Blind Trial to Determine the Effectivenss of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome
Trial Type: Clinical

Protocol Document: R0433
Protocol Number: R0433
Phase III International Randomized Trial of Single vs. Multiple Fractions for Re-Irradiation of Painful Bone Metastases
Trial Type: Clinical

Protocol Document: RC05CB
Protocol Number: RC05CB
A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every 3 Week Epoetin Alfa and Every 3 Week Darbepoetin Alfa
Trial Type: Clinical

Protocol Document: S0424
Protocol Number: S0424
Molecular Epidemiology Case-Series Study of Non-Small CellLung Cancer in Smoking and Non-Smoking Women and Men
Trial Type: Clinical

Protocol Document: E5202
Protocol Number: E5202
Randomized Phase III Study Comparing 5FU, Leucovorin and Oxaliplatin vs. 5FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Marks
Trial Type: Clinical

Protocol Document: N0147 - CLOSED TO > 70 YRS. OLD
Protocol Number: N0147 - CLOSED TO >70 YRS. OLD
A RANDOMIZED PHASE III TRIAL OF IRINOTECAN (CPT-11) AND/OR OXALIPLATIN (OXAL) PLUS 5-FLUOROURACIL (5-FU)/LEUCOVORIN (CF) WITH OR WITHOUT CETUXIMAB (C225) AFTER CURATIVE RESECTION FOR PATIENTS WITH STAGE III COLON CANCER
Trial Type: Clinical

Protocol Document: N0346
Protocol Number: N0346
Phase II Trial of Celecoxib and Capecitabine Combined with Pelvic Irradiation as Neoadjuvant Treatment of Stage II or III Adenocarcinoma of the Rectum
Trial Type: Clinical

Protocol Document: CALGB-80101
Protocol Number: CALGB-80101
PHASE III INTERGROUP TRIAL OF ADJUVANT CHEMORADIATION AFTER RESECTION OF GASTRIC OR GASTROESOPHAGEAL ADENOCARCINOMA
Trial Type: Clinical

Protocol Document: CALGB 80405 - SUSPENDED
Protocol Number: CALGB 80405 - SUSPENDED
Phase III Trial of Irinotecan/5FU/Leucovorin or Oxaliplatin/5FU/Leucovorin with Bevacizumab, or Cetuximab (C225) or With The Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Trial Type: Clinical

Protocol Document: S0600 - SUSPENDED
Protocol Number: S0600 - SUSPENDED
Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab With or Without Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who Have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX, or XELOX
Trial Type: Clinical

Protocol Document: E3205 SUSPENDED
Protocol Number: E3205 SUSPENDED
Phase II Trial of Cetuximab Plus Cisplatin, 5 FU and Radiation in Immunocompetent Patients with Anal Carcinoma
Trial Type: Clinical

Protocol Document: E5204
Protocol Number: E5204
Intergroup Randomzied Phase III Study of Postoperative Oxaliplatin, 5FU, and Leucovorin vs. Oxaliplatin, 5FU, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation
Trial Type: Clinical

Protocol Document: N0543
Protocol Number: N0543
Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Trial Type: Clinical

Protocol Document: S0502
Protocol Number: S0502
A Phase IIIRandomized Trial of Imatinib, With or Without Bevacizumab (NSC-704865) in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
Trial Type: Clinical

Protocol Document: CALGB 90401
Protocol Number: CALGB 90401
Randomized Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with and without Bevacizumab in Men with Hormone Refractory Prostate Cancer
Trial Type: Clinical

Protocol Document: E5805
Protocol Number: E5805
Phase II Trial of E7389 (Halichondrin b Analog) in Patients with Metastatic Hormone Refractory Prostate Cancer
Trial Type: Clinical

Protocol Document: R0232
Protocol Number: R0232
Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma
Trial Type: Clinical

Protocol Document: R0521
Protocol Number: R0521
Phase III Protocol of Adrogen Suppression and 3 DCRT/IMRT vs. AS and 3 DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer
Trial Type: Clinical

Protocol Document: R0534
Protocol Number: R0534
Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (Sport) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy
Trial Type: Clinical

Protocol Document: S0421
Protocol Number: S0421
Phase III Study of Docetaxel and Atrasentan vs. Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer
Trial Type: Clinical

Protocol Document: E2804
Protocol Number: E2804
A Randomized Phase II Study of VEGF, RAF Kinase, and MTOR Combination GTargeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma
Trial Type: Clinical

Protocol Document: E2805
Protocol Number: E2805
Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib vs. Sorafenib vs. Placebo in Patients with Resected Renal Cell Carcinoma
Trial Type: Clinical

Protocol Document: GOG-0209
Protocol Number: GOG-0209
Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel/G-CSF vs. Carboplatin/Paclitaxel in Patients with Stage III + IV or Recurrent Endometrial Cancer
Trial Type: Clinical

Protocol Document: GOG 0218
Protocol Number: GOG 0218
A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo vs. Carboplatin and Paclitaxel Plus Concurrent Bevacizumab Followed by Placebo, vs. Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed, Previously Untreated, Stage III (Suboptimal) and All Stage IV, Epithelial Ovarian or Primary Peritoneal Cancer
Trial Type: Clinical

Protocol Document: H6Q-MC-JCBJ
Protocol Number: H6Q-MC-JCBJ
Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
Trial Type: Clinical

Protocol Document: CALGB 10501
Protocol Number: CALGB 10501
Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention vs. Observation with Later Treatment in High Risk Genetic Subset with IgVh Unmutated Disease
Trial Type: Clinical

Protocol Document: N0683
Protocol Number: N0683
Phase II Study of Sunitinib Malate for Treatment of Patients wtih Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Trial Type: Clinical

Protocol Document: N038H
Protocol Number: N038H
Phase II Study of CCI-779 in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma
Trial Type: Clinical

Protocol Document: E1A05
Protocol Number: E1A05
Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade), Lenalidomide (Revlimid), Dexamethasone (VRD) vs. Bortezomib, Dexamethasone for Patients with Multiple Myeloma Who Have Completed A Dexamethasone Based Induction Regimen
Trial Type: Clinical

Protocol Document: S0535
Protocol Number: S0535
A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia
Trial Type: Clinical

Protocol Document: E1504
Protocol Number: E1504
Phase II Study of C225 (Cetuximab) for the Treatment of Patients with Advanced Bronchioalveolar Carcinoma or Adenocarcinoma with BAC Features
Trial Type: Clinical

Protocol Document: S0220
Protocol Number: S0220
A PHASE II TRIAL OF INDUCTION CHEMORADIOTHERAPY WITH CISPLATIN/ETOPOSIDE FOLLOWED BY SURGICAL RESECTION, FOLLOWED BY DOCETAXEL, FOR NON-SMALL CELL LUNG CANCER INVOLVING THE SUPERIOR SULCUS (PANCOAST TUMORS)
Trial Type: Clinical

Protocol Document: E1505
Protocol Number: E1505
Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB - IIIA Non-Small Cell Lung Cancer
Trial Type: Clinical

Protocol Document: R0617 - expired
Protocol Number: R0617 - expired
A Rnaodmized Phase III Comparison of Standard Dose (60 Gy) vs. High Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer
Trial Type: Clinical

Protocol Document: E1697
Protocol Number: E1697
Randomized Study of Four Weeks High Dose IFN-12B In Stage IIA Melanoma
Trial Type: Clinical

Protocol Document: N0775
Protocol Number: N0775
Randomized Phase II Trial of Temozolomide (TMZ) and Avastin or ABI-007/Carboplatin (CBDCA) and Avastin in Patients with Unresectable Stage IV Malignant Melanoma
Trial Type: Clinical

Protocol Document: N0392 - NCCTG Companion Study
Protocol Number: N0392 - NCCTG Companion Study
Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical trials
Trial Type: Clinical

Protocol Document: 20062080
Protocol Number: 20062080
Phase 2, Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Trial Type: Clinical

Protocol Document: C05009, Limited call TCHOP
Protocol Number: C05009, Limited call TCHOP
Randomized Phase IIIB Study of Three Treatment Regimens in Subjects with Previously Untraeted Multiple Myeloma Who Are Not Considered Candidates for High Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE (Bortezomib), Thalidomide, and Dexamethasone (VTD) vs VELCADE and Dexamethasone (VD) vs VELCADE, Melphalana nd Prednisone (VMP)
Trial Type: Clinical

Protocol Document: AVF3991 - limited; call TCHOP
Protocol Number: AVF3991 - limited; call TCHOP
An Observational Study of Avastin in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer, Locally Advanced or Metastatic Non-Small Cell Lung (Excluding Predominant Squamous Cell Histology, or Locally Recurrent of Metastatic Breast Cancer)
Trial Type: Clinical

Protocol Document: S0437
Protocol Number: S0437
Prostate Cancer Prevention Trial (PCPT) Companion Long-Term Follow-Up Study for Men Diagnosed with Prostate Cancer
Trial Type: Clinical